Rapha Capital Management, LLC — 2018 Investments
1 investments dated 2018 · listed companies and verified rows first · show all
AsclepiX Therapeutics, Inc.asclepix.cominNov 2018 · $5M
Biopharmaceutical company using computational biology to identify and develop novel peptide therapies, including AXT107 for retinal/eye diseases.
BiotechBethesda, US
Aleksander S. Popel, PhD(Executive Officer, Director)Jordan J. Green(Executive Officer, Director)inWendy Perrow(Executive Officer, Director)in
PartnerKevin M. Slawin· solo GP
Co-investorsPerceptive Xontogeny Venture
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.